Trial
NCT01900496
Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators
Genentech, Inc.
Condition
Lymphoma
Intervention
Brentuximab vedotin
Why stopped
Low accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-10-17